CN110003174A - 一种盐酸盐化合物的制备方法 - Google Patents

一种盐酸盐化合物的制备方法 Download PDF

Info

Publication number
CN110003174A
CN110003174A CN201811593540.XA CN201811593540A CN110003174A CN 110003174 A CN110003174 A CN 110003174A CN 201811593540 A CN201811593540 A CN 201811593540A CN 110003174 A CN110003174 A CN 110003174A
Authority
CN
China
Prior art keywords
formula
compound
method described
mixture
generate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811593540.XA
Other languages
English (en)
Chinese (zh)
Inventor
房极赞
文荣沪
张永佶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Holdings Co Ltd
Original Assignee
Hanmi Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48044309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110003174(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Holdings Co Ltd filed Critical Hanmi Holdings Co Ltd
Publication of CN110003174A publication Critical patent/CN110003174A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201811593540.XA 2011-10-05 2012-10-05 一种盐酸盐化合物的制备方法 Pending CN110003174A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2011-0101422 2011-10-05
KR1020110101422A KR101272613B1 (ko) 2011-10-05 2011-10-05 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체
CN201280049302.7A CN103857672B (zh) 2011-10-05 2012-10-05 用于制备1-(4-(4-(3,4-二氯-2-氟苯氨基)-7-甲氧基喹唑啉-6-基氧基)哌啶-1-基)-丙-2-烯-1-酮盐酸盐的方法及其中使用的中间产物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280049302.7A Division CN103857672B (zh) 2011-10-05 2012-10-05 用于制备1-(4-(4-(3,4-二氯-2-氟苯氨基)-7-甲氧基喹唑啉-6-基氧基)哌啶-1-基)-丙-2-烯-1-酮盐酸盐的方法及其中使用的中间产物

Publications (1)

Publication Number Publication Date
CN110003174A true CN110003174A (zh) 2019-07-12

Family

ID=48044309

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811593540.XA Pending CN110003174A (zh) 2011-10-05 2012-10-05 一种盐酸盐化合物的制备方法
CN201280049302.7A Active CN103857672B (zh) 2011-10-05 2012-10-05 用于制备1-(4-(4-(3,4-二氯-2-氟苯氨基)-7-甲氧基喹唑啉-6-基氧基)哌啶-1-基)-丙-2-烯-1-酮盐酸盐的方法及其中使用的中间产物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280049302.7A Active CN103857672B (zh) 2011-10-05 2012-10-05 用于制备1-(4-(4-(3,4-二氯-2-氟苯氨基)-7-甲氧基喹唑啉-6-基氧基)哌啶-1-基)-丙-2-烯-1-酮盐酸盐的方法及其中使用的中间产物

Country Status (23)

Country Link
US (1) US8859767B2 (enExample)
EP (2) EP3611172A1 (enExample)
JP (1) JP5805880B2 (enExample)
KR (1) KR101272613B1 (enExample)
CN (2) CN110003174A (enExample)
AU (1) AU2012319291B2 (enExample)
BR (1) BR112014007718B1 (enExample)
CA (1) CA2850055C (enExample)
CY (1) CY1122758T1 (enExample)
DK (1) DK2763981T3 (enExample)
ES (1) ES2775197T3 (enExample)
HR (1) HRP20200426T1 (enExample)
HU (1) HUE048798T2 (enExample)
IL (3) IL231911B (enExample)
IN (1) IN2014DN03447A (enExample)
LT (1) LT2763981T (enExample)
MX (1) MX348815B (enExample)
PL (1) PL2763981T3 (enExample)
PT (1) PT2763981T (enExample)
RS (1) RS60118B1 (enExample)
RU (1) RU2563630C1 (enExample)
SI (1) SI2763981T1 (enExample)
WO (1) WO2013051883A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
JP6704422B2 (ja) 2015-03-20 2020-06-03 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. キナゾリン誘導体の塩およびその製造方法
KR102802129B1 (ko) * 2018-09-14 2025-05-02 한미약품 주식회사 퀴나졸린 화합물 및 이의 염산염의 결정 형태
KR101950942B1 (ko) * 2019-01-28 2019-02-22 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
US20210221792A1 (en) * 2020-01-16 2021-07-22 Hanmi Pharm Co., Ltd. Convergent synthesis of poziotinib derivative
WO2022043923A1 (en) * 2020-08-28 2022-03-03 Hanmi Science Co., Ltd. Synthesis of poziotinib derivative

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030765A1 (en) * 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives as antiproliferative agents
CN101679384A (zh) * 2007-06-05 2010-03-24 韩美药品株式会社 用于抑制癌细胞生长的新酰胺衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
DE602004004811T2 (de) * 2003-09-19 2007-11-22 Astrazeneca Ab Chinazolinderivate
JP2009518450A (ja) * 2005-12-12 2009-05-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式複素環化合物、その化合物を含む薬剤、その使用及び製造方法
US8450482B2 (en) * 2009-04-23 2013-05-28 Astrazeneca Ab Process for the preparation of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-([1-(N-methylcarbamoymethyl)piperidin-4-yl]oxy)quinazoline

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030765A1 (en) * 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives as antiproliferative agents
CN101679384A (zh) * 2007-06-05 2010-03-24 韩美药品株式会社 用于抑制癌细胞生长的新酰胺衍生物

Also Published As

Publication number Publication date
HUE048798T2 (hu) 2020-08-28
EP2763981A2 (en) 2014-08-13
LT2763981T (lt) 2020-05-25
ES2775197T3 (es) 2020-07-24
DK2763981T3 (da) 2020-03-16
JP2014528444A (ja) 2014-10-27
EP2763981B1 (en) 2020-01-08
CN103857672B (zh) 2018-11-30
JP5805880B2 (ja) 2015-11-10
WO2013051883A2 (en) 2013-04-11
CA2850055E (en) 2013-04-11
EP2763981A4 (en) 2015-02-25
CA2850055C (en) 2016-05-17
US20140275534A1 (en) 2014-09-18
CA2850055A1 (en) 2013-04-11
IL231911A0 (en) 2014-05-28
US8859767B2 (en) 2014-10-14
IN2014DN03447A (enExample) 2015-06-26
BR112014007718A2 (pt) 2017-04-25
RS60118B1 (sr) 2020-05-29
PT2763981T (pt) 2020-03-25
PL2763981T3 (pl) 2020-08-10
RU2563630C1 (ru) 2015-09-20
EP3611172A1 (en) 2020-02-19
IL259694A (en) 2018-07-31
BR112014007718B1 (pt) 2022-02-22
CY1122758T1 (el) 2021-03-12
MX2014003959A (es) 2014-05-14
CN103857672A (zh) 2014-06-11
IL291738A (en) 2022-05-01
WO2013051883A3 (en) 2013-06-06
IL231911B (en) 2018-06-28
HRP20200426T1 (hr) 2020-09-04
SI2763981T1 (sl) 2020-07-31
KR20130037079A (ko) 2013-04-15
KR101272613B1 (ko) 2013-06-10
AU2012319291A1 (en) 2014-05-22
IL259694B (en) 2022-04-01
MX348815B (es) 2017-06-30
AU2012319291B2 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
CN103857672B (zh) 用于制备1-(4-(4-(3,4-二氯-2-氟苯氨基)-7-甲氧基喹唑啉-6-基氧基)哌啶-1-基)-丙-2-烯-1-酮盐酸盐的方法及其中使用的中间产物
JP7377307B2 (ja) １－（４－（４－（３，４－ジクロロ－２－フルオロフェニルアミノ）－７－メトキシキナゾリン－６－イルオキシ）ピペリジン－１－イル）プロパ－２－エン－１－オンの製造方法
US9890179B2 (en) Methods of preparing cytotoxic benzodiazepine derivatives
WO2015007249A1 (zh) N-烷基色胺酮衍生物及其制备方法和应用
WO2017186140A1 (zh) 一种制备酪氨酸激酶抑制剂及其衍生物的方法
CN109384785B (zh) 吡咯并吡啶酮类衍生物、其制备方法及其在医药上的用途
US8519176B1 (en) Process for preparation of substituted P-aminophenol
HK1196132B (zh) 用於制备1-(4-(4-(3，4-二氯-2-氟苯氨基)-7-甲氧基喹唑啉-6-基氧基)哌啶-1-基)-丙-2-烯-1-酮盐酸盐的方法及其中使用的中间产物
CN101652357B (zh) 喹诺酮羧酸衍生物的制备方法
HK40010388A (en) Preparation method for hydrochloride compound
HK1196132A (en) Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-one hydrochloride and intermediates used therein
CN110669027A (zh) 化合物和其酯、其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40010388

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190712

WD01 Invention patent application deemed withdrawn after publication